Clinical Trial

RCT of CBD for Anxiety in Advanced Breast Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This research study is investigating use of a single dose of cannabidiol (CBD) to help manage anticipatory anxiety in participants with advanced breast cancer poised to undergo computed tomography (CT) or positron emission tomography (PET) to assess tumor burden. The name of the study drug(s) are: \- Cannabidiol (CBD)
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2020-07-21; most recent amendment 2025-07-28.
Status change: Recruiting → Active, Not Recruiting 2024-01-08
Status change: Not Yet Recruiting → Recruiting 2022-02-02
Trial Details
NCT Number NCT04482244
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Hans and Mavis Lopater Foundation
Conditions Advanced Breast Cancer, Anxiety, CBD
Enrollment 60 participants
Start Date 2022-01-19
Primary Completion 2023-03-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-29